Please use this identifier to cite or link to this item:
|Title:||Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study|
Saltz, Leonard B.
Northern Clinical School: Kolling Institute
|Publisher:||American Society of Clinical Oncology|
|Citation:||Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study, Journal of Clinical Oncology, vol.26, 12, 2008,pp 2013-2019|
|Department/Unit/Centre:||Northern Clinical School: Kolling Institute|
|Disclaimer:||This work has been made available to the staff and students of the University of Sydney for the purposes of research and study only. It constitutes material that is held by the University for the purposes of reporting for HERDC and the ERA. This work may not be downloaded, copied and distributed to any third party .|
|Type:||C1 - Refereed Journal articles|
|Appears in Collections:||University of Sydney Research Outputs|
Items in Sydney Research Online are protected by copyright, with all rights reserved, unless otherwise indicated.